Fosfor and Snowflake Deepen Joint Commitment to Enable Faster and Better Decisions for Enterprises with GPT, Snowpark, and Streamlit Integrations
Fosfor, the Data Products Unit of LTIMindtree [NSE: LTIM, BSE: 540005], today announced a series of new integrations with Snowflake at its annual user conference, Snowflake Summit 2023. These integrations will allow Snowflake customers to leverage the Data Cloud to realize the full power of the Fosfor Decision Cloud, accelerating their adoption of Artificial Intelligence (AI) and Machine Learning (ML) workloads and optimizing decision intelligence capabilities at enterprise scale. The announcement comes on the heels of the Fosfor product suite being certified as a Snowflake Ready technology.
A growing number of businesses are pursuing business transformation by leveraging the power of Snowflake Data Cloud. The Fosfor Decision Cloud helps enterprises further maximize the business value of their data in the Data Cloud by providing:
- Generative AI to enhance productivity in the ML build lifecycle and democratize insights consumption: Refract Wave, the newest capability in the Refract ML Engineering product, now integrates with GAI to help ML architects with faster data onboarding and effortless execution of ML pipelines. Lumin Flow, a new capability of Fosfor’s decision intelligence product, is powered by GPT, making it possible for Snowflake customers to get actionable insights quickly, safely, and securely.
- Streamlit integration to create apps to scale the accessibility of insights: Refract’s Streamlit integration enhances the model performance of existing Streamlit apps and simplifies the creation of custom models for new applications. Lumin provides a Streamlit SDK pack, combining the Snowflake tech stack with Lumin’s decision intelligence capabilities.
- Snowpark integration to accelerate the generation of insights within the Snowflake ecosystem: Refract’s Snowpark integration provides a simple, end-to-end integrated workbench for ML workloads on Snowpark, which reduces both the time and complexity required for data science and ML practitioners to achieve their goals. With Refract, ML models can be run directly on Snowflake by leveraging Snowpark, ensuring real-time insights, better data governance, and higher quality decisions on the Data Cloud. Lumin’s natural language search capability and NLP-based insights enable customers to fully exploit the power of Snowpark and aid new use cases, which were not previously possible, while optimizing TCO and simplifying infrastructure needs.
- Pre-built industry solutions leveraging the combined power of Fosfor and the Data Cloud: Fosfor is rolling out a series of Snowflake-integrated industry solutions to address insight-related use cases commonly faced by Data Cloud users. These include FinOps insights, marketing campaign analytics, nursing attrition analytics, and IT incident analytics on ServiceNow using Snowflake’s native ServiceNow connector.
Extending the depth of its platform, Fosfor — combined with Snowflake’s best-in-class cloud technology — is unlocking new ways to transform the industry and accelerate data-driven outcomes for customers.
“Fosfor and Snowflake are united in our shared goal of enabling the new breed of data-driven enterprises. With Refract’s native integration with Snowpark, we’re giving builders the data access and tools they need to securely accelerate their innovation pace under Snowflake’s unified platform. By bringing the power of GPT to Lumin, our vision is to democratize decision making on the Data Cloud,” said Debasis Satpathy, Chief Business Officer, Fosfor. “We are thrilled to deepen our Snowflake partnership and see our combined efforts accelerate the journey from data to optimized business decisions seamlessly and at scale.”
“We are excited that Fosfor is introducing new and unique Generative AI, Snowpark, and Streamlit innovations to enhance its integrations with the Snowflake Data Cloud,” said Krishnan Parasuraman, Vice President, Field CTO Office, Snowflake. “Fosfor’s announcements represent an important milestone in our continued partnership as we focus on helping customers across the globe easily and securely get actionable insights from their data.”
At the Snowflake Summit 2023 in Las Vegas, happening June 26-29, 2023, attendees can get a glimpse of the latest features and much more at the Fosfor Booth, number 2741.
Be sure to check out the Snowflake Summit 2023 keynotes live or on-demand here and stay on top of the latest news and announcements from Snowflake on LinkedIn and Twitter.
Learn more about Refract and Lumin, or meet us at the Snowflake Summit 2023.
About Fosfor
The Fosfor Decision Cloud is the only end-to-end suite for optimizing all aspects of the data-to-decisions lifecycle. Fosfor helps you make better decisions, ensuring you have the right data in more hands in the fastest time possible. The Fosfor Decision Cloud is made up of Spectra, a comprehensive DataOps product; Refract, a data science and MLOps product; and Lumin, a decision intelligence product. Taken together, the Fosfor suite helps businesses discover the hidden value in their data. The Fosfor Data Products Unit is part of LTIMindtree, a global technology consulting and digital solutions company with hundreds of clients and operations in more than 30 countries. For more information, visit www.fosfor.com.
About LTIMindtree
LTIMindtree is a global technology consulting and digital solutions company that enables enterprises across industries to reimagine business models, accelerate innovation, and maximize growth by harnessing digital technologies. As a digital transformation partner to more than 700 clients, LTIMindtree brings extensive domain and technology expertise to help drive superior competitive differentiation, customer experiences, and business outcomes in a converging world. Powered by 84,000+ talented and entrepreneurial professionals across more than 30 countries, LTIMindtree — a Larsen & Toubro Group company — combines the industry-acclaimed strengths of erstwhile Larsen and Toubro Infotech and Mindtree in solving the most complex business challenges and delivering transformation at scale. For more information, please visit https://www.ltimindtree.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230626463263/en/
Contact information
Media Contact
media@ltimindtree.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom